STOCK TITAN

Bausch Health Companies (BHC) Stock News, Oct 2025-Jan 2026

BHC NYSE

Bausch Health Companies Inc. reports news on its global diversified pharmaceutical business, including financial results, guidance, debt refinancing activity and updates from its operating businesses. The company develops, manufactures and markets products in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health through its controlling interest in Bausch + Lomb.

Recurring company updates include Salix gastroenterology programs, Ortho Dermatologics skincare and patient-support initiatives, Solta Medical aesthetic device launches, and quarterly performance for Bausch Health excluding Bausch + Lomb. News also covers product availability, regulatory clearances for medical aesthetic devices, clinical-program disclosures and capital-structure actions.

Rhea-AI Summary

Bausch Health (NYSE: BHC) will release its fourth quarter and full year 2025 financial results after market close on Wednesday, February 18, 2026. The company will host a live conference call and webcast at 5:00 p.m. U.S. EST to discuss results and provide a business update. Presentation materials and a replay of the call will be made available on the company's Investor Relations website prior to and after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.06%
Tags
earnings date
-
Rhea-AI Summary

Bausch Health (NYSE:BHC) announced that CEO Thomas J. Appio will participate at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026. Executive attendees include EVP/CFO Jean-Jacques Charhon and EVP/CMO & Head of R&D Jonathan Sadeh, M.D..

A live audio webcast will be accessible via the company's Investor Relations website at http://ir.bauschhealth.com/events-and-presentations, with a replay available after the event. Time: 3:45 p.m. PT / 6:45 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.64%
Tags
none
-
Rhea-AI Summary

Bausch Health (NYSE:BHC) announced final results and expiration of exchange offers for its outstanding 4.875% and 11.00% Senior Secured Notes due 2028. The offers expired on December 23, 2025. Holders validly tendered an aggregate of $2.7 billion of existing notes; the Offerors accepted existing notes resulting in approximately $1.6 billion principal amount of new 10.00% Senior Secured Notes due 2032, with settlement currently expected on December 26, 2025. The New Notes are unregistered in the U.S. and Canada and will be issued pursuant to the exchange terms described in the exchange offer memorandum.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.91%
Tags
none
Rhea-AI Summary

Bausch Health (NYSE:BHC) announced early results of exchange offers to swap its outstanding 4.875% and 11.00% senior secured notes due 2028 for up to $1.6 billion aggregate principal of new 10.00% senior secured notes due 2032 issued by subsidiary 1261229 B.C. Ltd.

As of 5:00 p.m. ET on December 8, 2025, holders validly tendered $2,690,016,000 of existing notes, and the company expects to issue approximately $1,600 million of New Notes after applying the Maximum Notes Amount and proration. The Withdrawal Deadline passed on December 8; the Offers expire at 5:00 p.m. ET on December 23, 2025, with settlement expected within three business days after expiration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.29%
Tags
none
-
Rhea-AI Summary

Bausch Health (NYSE:BHC) announced that its aesthetic business, Solta Medical, completed the acquisition of Wuhan Shibo Zhenmei Technology Co., Ltd., the Shibo group's aesthetics distribution business, effective December 1, 2025. The Shibo group, a distribution partner for more than a decade, becomes a wholly owned Solta Medical subsidiary in China and assumes full responsibility for distributing Solta Medical products, including Thermage FLX.

The transaction is intended to deepen local presence, provide direct customer insight, speed market execution, and support growing demand for aesthetic treatments in China.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.02%
Tags
-
Rhea-AI Summary

Bausch Health (NYSE:BHC) commenced offers on November 24, 2025 to exchange up to $1.6 billion aggregate principal of its outstanding 4.875% and 11.00% Senior Secured Notes due 2028 for new 10.00% Senior Secured Notes due 2032 issued by a wholly owned subsidiary.

Key terms: Exchange Consideration per $1,000 is $787.50 (4.875% notes) and $920.00 (11.00% notes); an Early Exchange Premium $100 per $1,000 applies for tenders by Dec 8, 2025; offers expire Dec 23, 2025. New Notes will be fungible with the issuer's existing 10.00% notes due 2032 and are subject to eligibility, customary conditions and a transaction support agreement covering ~$1,545 million of existing notes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.33%
Tags
none
Rhea-AI Summary

Bausch Health (NYSE:BHC) said Jean-Jacques Charhon, executive vice president and chief financial officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference in Coral Gables, Florida on December 2, 2025.

The session is scheduled for 10:50 a.m. – 11:10 a.m. ET and a live audio webcast will be available via the company’s Investor Relations website at http://ir.bauschhealth.com/events-and-presentations. A replay will be posted on the investor site after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.82%
Tags
none
-
Rhea-AI Summary

Bausch Health (NYSE:BHC) and its dental business OraPharma announced commercial expansion of Arestin into Canada and Puerto Rico on November 5, 2025, aiming to improve access to periodontal disease treatments and strengthen distributor and dental professional partnerships.

Arestin is described as the only FDA‑approved locally applied antibiotic for use with scaling and root planing and is supported by over 20 years of clinical experience. The release highlights high regional disease prevalence and includes safety and prescribing information for Arestin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary

Bausch Health (NYSE:BHC) reported third quarter 2025 consolidated revenue of $2.68 billion, up 7% year-over-year (5% organic), GAAP net income attributable to Bausch Health of $179 million, and consolidated adjusted EBITDA (non-GAAP) of $986 million (includes an $81 million acquired IPR&D charge).

Key operational highlights: tenth consecutive quarter of year-over-year revenue and adjusted EBITDA growth excluding Bausch + Lomb; completed acquisition of DURECT and added Larsucosterol with FDA Breakthrough Therapy Designation; redeemed ~$601 million of 9.25% notes and repaid a $300 million receivables facility post-quarter. Company raised full-year 2025 revenue and adjusted EBITDA guidance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.03%
Tags
Rhea-AI Summary

Bausch Health (NYSE: BHC) announced that shareholders approved the Amended and Restated Shareholder Rights Plan Agreement at a special meeting held on October 7, 2025. The Rights Plan is dated April 14, 2025 and was amended and restated on August 25, 2025. The company said the final vote tabulation will be filed with the U.S. SEC on a Form 8-K and will be available on SEDAR+ and the company website.

This notice confirms shareholder ratification, and indicates the company will publicly report the detailed vote results via regulatory and company channels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none

FAQ

What is the current stock price of Bausch Health Companies (BHC)?

Bausch Health Companies (BHC) last closed at $8.22.

What is the market cap of Bausch Health Companies (BHC)?

The market cap of Bausch Health Companies (BHC) is approximately $3.1B.